Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

L'Oreal sales rise 9.4% as mass market makeup outshines luxury

Published 04/18/2024, 12:17 PM
Updated 04/18/2024, 02:36 PM
© Reuters. FILE PHOTO: The logo of French cosmetics group L'Oreal is seen on a company building in Paris, France, February 7, 2024. REUTERS/Sarah Meyssonnier/File Photo

By Dominique Patton and Mimosa Spencer

PARIS (Reuters) -L'Oreal reported a 9.4% rise in first quarter sales on a like-for-like basis on Thursday, beating expectations and easing concerns about a slowdown in the two biggest beauty markets the United States and China.

The French cosmetics giant, which owns the Maybelline and Lancome brands, reported sales of 11.24 billion euros ($11.98 billion) for the first three months to the end of March.

The sales growth exceeded a consensus of a 6.1% rise cited by analysts at Jefferies. Sales were up 8.3% on a reported basis.

L'Oreal, the world's biggest beauty company, said sales in both North America and Europe grew by more than 12%, as its mass market range and dermatological products compensated for weakness in the luxury segment.

The West "continues to power on," Jefferies analysts said following the results, adding North America had defied weakening scanner data and downbeat retailer commentary.

U.S. retailer Ulta Beauty (NASDAQ:ULTA) earlier this month rattled the market with comment about a faster-than-expected slowdown in the United States that hit shares across the sector.

Following Thursday's results, L'Oreal's American depositary receipts (ADRs) gained as much as 6.5% in New York trading, while shares in U.S. rivals Estee Lauder (NYSE:EL) and Coty (NYSE:COTY) also rose.

CONSUMER PRODUCTS

L'Oreal said its consumer products division, which includes its L'Oreal Paris range of mascaras and Elseve hair gloss and accounts for more than a third of its revenues, grew 11.1% on a like-for-like basis.

The company benefited from higher volumes as well as value in the unit, with strong demand in Europe and emerging markets.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The smaller but fast-growing dermatological beauty unit, which sells La Roche-Posay and CeraVe skincare, grew 21.9%, as it continued to benefit from medical recommendations.

Sales in the luxury division that markets fragrances such as YSL's Libre and Aesop products acquired last year, grew by 1.8%, beating expectations for a decline, as strong growth in Europe and North America helped offset softness in North Asia.

North Asia suffered from an unfavourable comparison base in Travel Retail and sluggish market growth in mainland China, the company said.

Jefferies analysts said travel retail sales were also dented by a Chinese government crackdown on resellers of foreign consumer products, known as "daigou".

L'Oreal has the biggest share of China's luxury beauty market, or about 34%, Chief Executive Nicolas Hieronimus told analysts on a call.

"We are unhappy about the fact that this market is not rebounding the way we expected it to rebound," he said, but added that the company is still outperforming the market.

The company grew 6.2% in China, compared to less than 1% in the broader market, he said.

Shares in L'Oreal, Europe's 6th most valuable listed company, with a market capitalisation of about 220 billion euro ($234.26 billion), have lost 6% so far this year, compared to a 5% fall at U.S. peer Estee Lauder.

($1 = 0.9383 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.